lobaplatin

Lobaplatin is a third-generation platinum-based antineoplastic (chemotherapy) drug developed by ASTA Medica AG in Germany. It acts primarily by binding to DNA, causing inter- and intra-strand crosslinks and DNA denaturation, which leads to inhibition of DNA replication and transcription, ultimately inducing cell death. Lobaplatin can also delay or inhibit DNA repair and affect the expression of the c-myc gene, which is associated with tumorigenesis, apoptosis, and cell proliferation. Compared to earlier platinum drugs like cisplatin (first generation) and carboplatin (second generation), lobaplatin offers similar or superior antitumor activity with reduced toxicity—especially less nephrotoxicity and gastrointestinal toxicity than cisplatin—and does not exhibit cross-resistance with cisplatin. Its main indications include metastatic breast cancer, small cell lung cancer, chronic myelogenous leukemia (CML), as well as other solid tumors such as neuroblastoma[1][2][3][5]. The drug is administered intravenously.

Brand names

洛铂

Other names

洛巴铂